<DOC>
	<DOCNO>NCT01920269</DOCNO>
	<brief_summary>In laboratory clinical study , intravesical electromotive drug administration increase mitomycin bladder uptake , improve clinical efficacy high-risk non-muscle invasive urothelial bladder cancer . The investigator ' aim compare transurethral resection bladder tumor adjuvant intravesical electromotive mitomycin transurethral resection adjuvant intravesical passive diffusion mitomycin transurethral resection alone patient primary stage pTa-pT1 grade G1-G2 urothelial bladder cancer Patients randomly assign : transurethral resection alone , transurethral resection adjuvant intravesical 40 mg passive diffusion mitomycin dissolve 50 ml sterile water infuse 60 minute week 6 week , transurethral resection adjuvant intravesical 40 mg electromotive mitomycin dissolve 100 ml sterile water 23 mA pulse electric current 30 minute week 6 week . Patients intravesical adjuvant electromotive passive diffusion mitomycin group disease-free 3 month induction treatment , schedule receive monthly intravesical instillation 10 month , dose method infusion initial assign treatment . All patient assess safety . The investigator ' primary endpoint recurrence rate disease-free interval . Analyses do intention treat .</brief_summary>
	<brief_title>Intravesical Adjuvant Electromotive Mitomycin-C</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>histologically proven primary stage pTapT1 urothelial bladder cancer , adequate bonemarrow reserve ( ie , whitebloodcell count ≥4000 × 10⁶ cell per L ; platelet count ≥120 × 10⁹/L ) , normal renal function ( ie , serum creatinine ≤123·76 μmol/L ) , normal liver function ( ie , serum glutamicoxaloacetic aminotransferase ≤42 U/L , serum glutamicpyruvic aminotransferase ≤48 U/L , total bilirubin ≤22 μmol/L ) , Eastern Cooperative Oncology Group performance status 0 2. nonurothelial carcinoma bladder ; previous concomitant grade G3 urothelial and/or carcinoma situ bladder ; urothelial carcinoma upper urinary tract urethra , ; previous intravesical treatment chemotherapeutic immunotherapeutic drug ; know allergy mitomycin ; bladder capacity le 200 mL ; untreated urinarytract infection ; severe systemic infection ( ie , sepsis ) ; treatment immunosuppressive drug ; urethral stricture would prevent endoscopic procedure catheterisation ; previous radiotherapy pelvis ; concurrent chemo therapy , radio therapy , treatment biological response modifier ; malignant disease within 5 year trial registration ( except adequately treat basalcell squamouscell skin cancer , situ cervical cancer ) ; pregnancy ; factor would preclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>non-muscle invasive bladder cancer</keyword>
	<keyword>intravesical chemotherapy</keyword>
	<keyword>mitomycin</keyword>
	<keyword>passive diffusion</keyword>
	<keyword>electromotive drug administration</keyword>
</DOC>